Cipla (CPLFY) Shiller PE Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cipla Shiller PE Ratio?

Note: If the price history is too short, we do not calculate current Shiller PE for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Cipla  (OTCPK:CPLFY) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cipla Shiller PE Ratio Related Terms


Cipla Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Cipla's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cipla Shiller PE Ratio Chart

Cipla Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cipla Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CPLFY vs ZTS: Shiller PE Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cipla's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cipla Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cipla's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cipla's Shiller PE Ratio falls into.



Cipla Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cipla's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Cipla's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.1031/167.3573*167.3573
=0.103

Current CPI (Jun. 2026) = 167.3573.

Cipla Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 0.066 105.961 0.104
201612 0.069 105.196 0.109
201703 -0.012 105.196 -0.018
201706 0.079 107.109 0.123
201709 0.082 109.021 0.125
201712 0.077 109.404 0.118
201803 0.035 109.786 0.053
201806 0.083 111.317 0.125
201809 0.067 115.142 0.097
201812 0.057 115.142 0.083
201903 0.065 118.202 0.091
201906 0.085 120.880 0.118
201909 0.083 123.175 0.113
201912 0.061 126.235 0.081
202003 0.042 124.705 0.056
202006 0.094 127.000 0.124
202009 0.111 130.118 0.143
202012 0.126 130.889 0.160
202103 0.070 131.771 0.089
202106 0.120 134.084 0.150
202109 0.119 135.847 0.146
202112 0.120 138.161 0.146
202203 0.060 138.822 0.072
202206 0.110 142.347 0.129
202209 0.122 144.661 0.142
202212 0.121 145.763 0.139
202303 0.079 146.865 0.090
202306 0.150 150.280 0.167
202309 0.169 151.492 0.187
202312 0.157 152.924 0.172
202403 0.140 153.035 0.153
202406 0.175 155.789 0.188
202409 0.192 157.882 0.204
202412 0.230 158.323 0.243
202503 0.175 157.552 0.185
202506 0.188 159.755 0.197
202509 0.192 162.289 0.197
202512 0.094 163.281 0.096
202603 0.075 164.272 0.076
202606 0.103 167.357 0.103

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cipla Business Description

Other Exchanges CIPLA:India500087:India
Address Ganpatrao Kadam Marg, Cipla House, Peninsula Business Park, Lower Parel, Mumbai, MH, IND, 400 013
Cipla Ltd is a drug manufacturing company that focuses on a variety of pharmaceutical products. The company's product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. The bulk of its sales are generated in India, although it maintains a large world-wide presence. Cipla's growth plan focuses on new product launches. It has two segments Pharmaceuticals and new ventures. It derives maximum revenue from Pharmaceuticals Segment.